Tango Therapeutics Past Earnings Performance
Past criteria checks 0/6
Tango Therapeutics's earnings have been declining at an average annual rate of -32.1%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 22% per year.
Key information
-32.1%
Earnings growth rate
7.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 22.0% |
Return on equity | -40.2% |
Net Margin | -278.5% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%
Mar 19Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans
Mar 06Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk
Jan 08Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)
Aug 12Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?
May 10Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer
Oct 20Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth
Oct 05Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 13Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M
Aug 10We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn
May 28We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow
Jan 06Revenue & Expenses BreakdownBeta
How Tango Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 37 | -102 | 36 | 0 |
30 Sep 23 | 38 | -100 | 34 | 0 |
30 Jun 23 | 34 | -107 | 33 | 0 |
31 Mar 23 | 25 | -111 | 31 | 0 |
31 Dec 22 | 25 | -108 | 30 | 0 |
30 Sep 22 | 24 | -101 | 28 | 0 |
30 Jun 22 | 24 | -92 | 25 | 0 |
31 Mar 22 | 36 | -71 | 21 | 0 |
31 Dec 21 | 37 | -58 | 18 | 0 |
30 Sep 21 | 40 | -45 | 15 | 0 |
30 Jun 21 | 22 | -52 | 13 | 0 |
31 Mar 21 | 9 | -56 | 11 | 0 |
31 Dec 20 | 8 | -52 | 10 | 0 |
31 Dec 19 | 25 | -14 | 8 | 1 |
Quality Earnings: TNGX is currently unprofitable.
Growing Profit Margin: TNGX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TNGX is unprofitable, and losses have increased over the past 5 years at a rate of 32.1% per year.
Accelerating Growth: Unable to compare TNGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TNGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: TNGX has a negative Return on Equity (-40.2%), as it is currently unprofitable.